Novel multiplex immunofluorescence-based tumor inflammation score provides apparent predictive biomarker in a phase I/II study of pembrolizumab with gemcitabine in patients with previously-treated adv
3 hours ago
- #Tumor Inflammation Score
- #NSCLC Immunotherapy
- #Predictive Biomarker
- The study evaluated a combination of gemcitabine and pembrolizumab in 16 previously-treated, immunotherapy-naïve advanced NSCLC patients, finding it safe but not synergistic compared to historical controls.
- A novel tumor inflammation score, based on multiplex immunofluorescence, integrated Treg/CD3 T cell proximity and overall T-cell density, correlating significantly with disease response (p < 0.002).
- High baseline frequencies of regulatory T cells near CD3 T cells were associated with improved treatment outcomes (p < 0.05).
- High autoantibody responses to tumor-associated antigens trended toward worse outcomes (p = 0.06), suggesting possible tumor immune escape mechanisms.
- This score demonstrated better predictive power than traditional biomarkers like PD-L1 expression, TMB, or gene expression profiles.